Fate Therapeutics Adds On
Fate Therapeutics, a La Jolla, Calif.-based stem cell biotech company focused on cell fate control, has acquired Verio Therapeutics Inc., an Ontario-based developer of drug candidates targeting the activation of endogenous stem cells. No financial terms were disclosed. Fate Therapeutics has raised $42 million from OVP Venture Partners, ARCH Venture Partners, Polaris Venture Partners and Venrock.
9 April 2010•4 mins read
